

saypha®

croma



FILLING WITH COMFORT

MDR* approved, aesthetic dermal filler

*Medical Device Regulation

Product information for
healthcare professionals

saypha[®] filler

Lidocaine



saypha[®] filler Lidocaine is a cross-linked hyaluronic acid dermal filler indicated to correct moderate to severe nasolabial folds and lip augmentation.¹ The incorporated Lidocaine, facilitates enhanced treatment comfort for your patients.^{1,2}

Product specifications¹

Concentration HA	2.3%
Crosslinking agent	BDDE (concentration ≤ 2 ppm)
Additional ingredients	0.75% sodium chloride, 0.24% disodium phosphate dodecahydrate, 0.05% sodium dihydrogen phosphate dihydrate, 0.3% lidocaine HCl (as anaesthetic), pH of 6.7-7.3.
Crosslinking degree	0.5-1.0%
Particle size	$\sim 316 \mu\text{m}$
Injection depth	Mid to deep dermis or submucosa
Needle	27 G x 1/2" thin wall Terumo [™] needle (CE 0197)
Packaging unit	1 box of 1 mL syringe
Indication	The viscoelastic implant is indicated to correct moderate to severe nasolabial folds and for lip augmentation.

Comfort Flow syringe

Designed for optimal and reliable handling.³

PREMIUM GLASS SYRINGE

**NEW PRIMARY LABEL:
EASY READABLE SCALE**

**CLEAR DIFFERENTIATION:
NEW COLOUR CODING FOR EVERY
PRODUCT**

**DEVELOPED AND TESTED TOGETHER
WITH HEALTHCARE PROFESSIONALS³**



Extrusion force

With a keen focus on every detail, the optimised HA fillers manufacturing process and meticulously designed syringe, ensure reliable extrusion force of saypha® products. **saypha® filler Lidocaine shows a constantly comparable extrusion force⁴**


Product	IF [N]
saypha® filler Lidocaine	12
Restylane Refyne Lidocaine	10
Belotero Balance Lidocaine	10
Teosyal RHA 2 Lidocaine	11
Juvéderm Ultra 2 Lidocaine	9

* all products were tested with 27G x 1/2" needles

Rheology Data

G' (G prime)

A high G' is one of the main parameters that influences the lifting⁵ and volumising^{6,7} capacities of HA fillers. saypha® filler Lidocaine was developed with a lower G' within saypha® portfolio, specifically for targeted application to correct moderate to severe facial nasolabial folds and for lip augmentation.^{1,8}



saypha[®] filler

Lidocaine

Clinically proven effectiveness & safety

for the correction of **nasolabial folds**⁹

A prospective, open-label, multicentre, post-market study to evaluate **safety and efficacy** of saypha[®] filler Lidocaine over **36 weeks** in **60 adult women and men** for the **correction of nasolabial folds** (NFLs).

Month 1

Almost all the subjects demonstrated improvement of NFLs^{a,1,9}

Month 6

Almost all the subjects demonstrated aesthetic improvement^{b,9}

Month 9

93% of the subjects were still “satisfied” or “very satisfied”^{c,9}

97% of the patients demonstrated improvement of NFLs^{a,1,9}



**Adverse device effects (ADEs)
were mild or moderate**^{d,9}

a. Out of 60 analysed subjects, 59 (98.3%) had improved their NLF severity by at least 1 grade on the NLF-SRS (Nasolabial Fold Severity Rating Scale) at week 4, 58 subjects (96.7%) at weeks 24 and 36 based on investigators' evaluation. b. 59 evaluated subjects (98.3%) had improved aesthetics (below score 4 of the GAIS) at week 4 and week 24. c. 56 of 60 subjects (93.3%) were very satisfied or satisfied with the treatment 36 weeks post-initial treatment. d. Adverse device events (ADEs) were mild or moderate and resolved at least 25 days post-onset.

Clinical benefits


THE LASTING IMPACT OF SATISFACTION^c
ENDURING FOR 9 OUT OF 10 TREATED
PATIENTS EVEN 9 MONTHS AFTER TREATMENT.⁹

THE FILLING EFFECT FOR NASOLABIAL
FOLDS LASTS UP TO 9 MONTHS.^{a,1,9}

ENHANCED TREATMENT COMFORT
FACILITATED BY **LIDOCAINE** AND
THE EXPERTISE OF THE HCP.^{1,2}

Artful Accuracy

Injection techniques for the correction of nasolabial folds.¹




- **Retrograde injection**

- » Introduction of the entire needle along the fold or skin depression and injecting while slowly withdrawing the needle¹⁰
- » Mid to deep dermis¹



- **Bolus technique**

- » Create a depot of filler deep at the centre of defect¹¹
- » Mid to deep dermis¹



- **Fan technique**

- » Fanning involves inserting the needle inferiorly on the fold and advancing it superiorly to the apex at the base of the nose¹² and placement of a row of linear threads, followed by an arc of linear threads emanating from a single injection point.¹¹
- » Mid to deep dermis¹



- **Cross-hatching technique**


- » Cross-hatching consists of a series of parallel linear threads injected at intervals of 5-10 mm followed by a new series of threads injected at right angles to the first set to form a grid.¹³
- » Mid to deep dermis¹



- **Serial puncture technique**

- » Serial puncture comprises numerous small injections. Each injection perforates the dermis followed by extrusion of a droplet of filler material into the appropriate layer. The needle is then withdrawn and repositioned a small distance away; this process is then repeated.¹¹
- » Mid to deep dermis¹

Real Results



Patient treated with saypha® filler Lidocaine for the correction of nasolabial folds with retrograde serial linear threading technique into the deep dermis. 0.2 mL per side.



Patient treated with saypha® filler Lidocaine for the correction of nasolabial folds with retrograde serial linear threading into the deep dermis. 0.5 mL per side.



saypha® rich



saypha® filler



saypha® filler Lidocaine



saypha® volume



saypha® volume Lidocaine



saypha® volume plus Lidocaine

References

- 1 Instruction for use (IFU)
- 2 Levy PM, De Boule K, Raspaldo H. Comparison of injection comfort of a new category of cohesive hyaluronic acid filler with preincorporated lidocaine and a hyaluronic acid filler alone. *Dermatol Surg.* 2009 Feb;35 Suppl 1:332-6; discussion 337. doi: 10.1111/j.1524-4725.2008.01045.x. PMID: 19207322.
- 3 Syringe design award <https://ifdesign.com/en/winner-ranking/project/quatroject/203634>
- 4 Data on file
- 5 de la Guardia C, Virno A, Musumeci M, Bernardin A, Silberberg MB. Rheologic and Physicochemical Characteristics of Hyaluronic Acid Fillers: Overview and Relationship to Product Performance. *Facial Plast Surg.* 2022 Apr;38(2):116-123. doi: 10.1055/s-0041-1741560. Epub 2022 Feb 3. PMID: 35114708; PMCID: PMC9503994.
- 6 Fundarò SP, Salti G, Malgapo DMH, Innocenti S. The Rheology and Physicochemical Characteristics of Hyaluronic Acid Fillers: Their Clinical Implications. *Int J Mol Sci.* 2022 Sep 10;23(18):10518. doi: 10.3390/ijms231810518. PMID: 36142430; PMCID: PMC9503994.
- 7 Stocks D, Sundaram H, Michaels J, Durrani MJ, Wortzman MS, Nelson DB. Rheological evaluation of the physical properties of hyaluronic acid dermal fillers. *J Drugs Dermatol.* 2011 Sep;10(9):974-80. PMID: 22052265.
- 8 Data on file
- 9 Grablowitz D, Sulovsky M, Höller S, Ivezic-Schoenfeld Z, Chang-Rodriguez S, Prinz M. Safety And Efficacy Of Princess® filler Lidocaine In The Correction Of Nasolabial Folds. *Clin Cosmet Invest Dermatol.* 2019 Nov 26;12:857-864. doi: 10.2147/CCID.S211544. PMID: 31819583; PMCID: PMC6885652 (Since 2018 the product range is named saypha®).
- 10 Data on file
- 11 Data on file
- 12 Bass LS. Injectable Filler Techniques for Facial Rejuvenation, Volumization, and Augmentation. *Facial Plast Surg Clin North Am.* 2015 Nov;23(4):479-88. doi: 10.1016/j.fsc.2015.07.004. PMID: 26505544
- 13 Data on file

Austria - Headquarters

CROMA-PHARMA GmbH
Industriezeile 6
2100 Leobendorf
Austria
E-Mail: office@cromapharma.com

For more information visit

Croma-Pharma UK
T: +44 118 206 6513
Info.uk@cromapharma.com
www.cromapharma.com/uk
 [cromapharmauk](https://www.instagram.com/cromapharmauk)

